FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission 30-patient pivotal study initiated, evaluating seizure reduction and ...

I never thought smart home tech was for me. Maybe that’s because my introduction to it was largely centered around my friends incessantly yelling “Hey Google!” whenever they wanted a light turned on ...

All the Latest Game Footage and Images from Encode Encore! A charming, slice-of-life indie RPG where you earn some sweet cash by trying out various part-time jobs—all in the name of getting your girl ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech on track to start a pivotal study next year. The Californian company’s ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Adrienne Maxwell Adrienne Maxwell is an editor covering AV gear. Her specialty ...

Curious how the Caesar Cipher works? This Python tutorial breaks it down in a simple, beginner-friendly way. Learn how to encode and decode messages using one of the oldest and most famous encryption ...

DNA-encoded libraries have numerous advantages over traditional screening methods, including easy identification of compounds and the large quantity of compounds that can be screened simultaneously.

The big picture: AMD finally revealed the specifications, pricing, and performance details of Radeon RX 9070 and Radeon RX 9070 XT graphics cards, with full reviews expected in the coming days. While ...

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D toward its Dravet syndrome program. The asset in question, dubbed ...